Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 2/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.60 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9507468 | 0.86 | CRHBP (0.64) | CRHBPCRHR2CES1CES2ALDH1A1 | |
| SCHEMBL873994 | 0.84 | HPGD (0.72) | CES1CES2ALDH1A1MEN1KMT2A | |
| SCHEMBL11264333 | 0.82 | CRHBP (0.59) | CRHBPCRHR2CES1CES2ALDH1A1 | |
| SCHEMBL7379932 | 0.82 | ATM (0.75) | CRHBPCRHR2CES1CES2ALDH1A1 | |
| SCHEMBL11674649 | 0.82 | CRHBP (0.59) | CRHBPCRHR2CES1CES2ALDH1A1 | |
| SCHEMBL133668 | 0.80 | KDM4E (0.67) | CES1CES2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL20679719 | 0.78 | CRHBP (0.55) | CRHBPCRHR2CES1CES2ALDH1A1 | |
| SCHEMBL7376588 | 0.78 | ALDH1A1 (0.89) | CRHBPCRHR2CES1CES2ALDH1A1 | |
| SCHEMBL9137746 | 0.78 | CRHBP (0.55) | CRHBPCRHR2CES1CES2ALDH1A1 | |
| SCHEMBL23511690 | 0.78 | HPGD (0.66) | ALDH1A1MEN1KMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4727818-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| CN-1206921-C | Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the N-hydroxy anilide-type | NOVO JYMEZ AS (DK) | 2005-06-22 | — | — | CN | claimed |
| US-6592867-B2 | Capable of killing or inhibiting microbial cells or micro-organisms in laundry, on hard surfaces, in water systems, on skin, on teeth or on mucous membranes | NOVOZYMES A/S (DK) | 2003-07-15 | — | — | US | claimed |
| EP-1128730-B1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | NOVOZYMES AS (DK) | 2003-05-02 | — | — | EP | claimed |
| JP-2002529380-A | — | — | 2002-09-10 | — | — | JP | claimed |
| US-20020094331-A1 | ANTIMICROBIAL COMPOSITION CONTAINING AN OXIDOREDUCTASE AND AN ENHANCER OF THER N-HYDROXYANILIDE-TYPE | NOVOZYMES A/S (DK) | 2002-07-18 | — | — | US | claimed |
| CN-1325270-A | Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the N-hydroxy anilide-type | NOVO JYMEZ AS (DK) | 2001-12-05 | — | — | CN | claimed |
| EP-1128730-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | Novozymes A/S (DK) | 2001-09-05 | — | — | EP | claimed |
| WO-2000027204-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | NOVOZYMES A/S (DK) | 2000-05-18 | — | — | WO | claimed |
| WO-2025242789-A1 | METHOD FOR PRODUCING REINFORCED TEXTILE FIBER COMPOSITIONS | LIGAMORE APS (DK) | 2025-11-27 | — | — | WO | disclosed |
| EP-3444337-B1 | METHOD OF CLEANING | PROCTER & GAMBLE (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-3444336-B1 | CLEANING AGENT | PROCTER & GAMBLE (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210147765-A9 | CLEANING KIT | THE PROCTER AND GAMBLE COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20210071117-A9 | CLEANING AGENT | THE PROCTER AND GAMBLE COMPANY | 2021-03-11 | — | — | US | disclosed |
| EP-1128730-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | Novozymes A/S (DK) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001048304-A1 | PROCESS FOR REMOVAL OF EXCESS DISPERSE DYE FROM PRINTED OR DYED TEXTILE MATERIAL | NOVOZYMES A/S (DK) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001023513-A1 | PARTICLES FOR LIQUID COMPOSITIONS | NOVOZYMES A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001010195-A1 | REDUCTION OF MALODOUR IN SOILED ANIMAL LITTER | NOVOZYMES A/S (DK) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000068324-A2 | ENZYMATIC PRESERVATION OF WATER BASED PAINTS | NOVOZYMES A/S (DK) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000027204-A1 | ANTIMICROBIAL COMPOSITION COMPRISING AN OXIDOREDUCTASE AND AN ENHANCING AGENT OF THE N-HYDROXYANILIDE-TYPE | NOVOZYMES A/S (DK) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094331-A1 | ANTIMICROBIAL COMPOSITION CONTAINING AN OXIDOREDUCTASE AND AN ENHANCER OF THER N-HYDROXYANILIDE-TYPE | LPO, MPO, LCT | CRHBP 4592/4885CRHR2 4730/4885CES1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.